Oncolytics Biotech secures FDA alignment for pivotal anal cancer trial

Filed April 27, 2026 · Period ending April 27, 2026 · ~1 min read

Key Changes

• high

  FDA agreed to design of controlled randomized pivotal study in squamous cell carcinoma of the anal canal, clearing path to potential marketing approval if trial succeeds.

  Item 8.01 Press Release verify on EDGAR →
• high

  Regulatory alignment represents critical milestone allowing company to advance late-stage development program with clear endpoint requirements.

  8-K: FDA Alignment verify on EDGAR →